This is the authors' abstract. We don't add key points for this paper.
// Filomena De Falco 1 , Rita Sabatini 1 , Beatrice Del Papa 2 , Franca Falzetti 2 , Mauro Di Ianni 3 , Paolo Sportoletti 2 , Stefano Baldoni 2 , Isabella Screpanti 4 , Pierfrancesco Marconi 1 and Emanuela Rosati 1 1 Department of Experimental Medicine, Biosciences and Medical Embryology Section, University of Perugia, Perugia, Italy 2 Department of Medicine, Hematology and Clinical Immunology Section, University of Perugia, Perugia, Italy 3 Department of Life, Health and Environmental Sciences, Hematology Section, University of L’Aquila, L’Aquila, Italy 4 Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy Correspondence to: Emanuela Rosati, email: // Keywords : chronic lymphocytic leukemia, Notch, Mcl-1, eIF4E, cell survival Received : February 20, 2015 Accepted : April 23, 2015 Published : May 12, 2015 Abstract In chronic lymphocytic leukemia (CLL), Notch1 and Notch2 signaling is constitutively activated and contributes to apoptosis resistance. We show that genetic inhibition of either Notch1 or Notch2, through small-interfering RNA, increases apoptosis of CLL cells and is associated with decreased levels of the anti-apoptotic protein Mcl-1. Thus, Notch signaling promotes CLL cell survival at least in part by sustaining Mcl-1 expression. In CLL cells, an enhanced Notch activation also contributes to the increase in Mcl-1 expression and cell survival induced by IL-4. Mcl-1 downregulation by Notch targeting is not due to reduced transcription or degradation by caspases, but in part, to increased degradation by the proteasome. Mcl-1 downregulation by Notch targeting is also accompanied by reduced phosphorylation of eukaryotic translation initiation factor 4E (eIF4E), suggesting that this protein is another target of Notch signaling in CLL cells. Overall, we show that Notch signaling sustains CLL cell survival by promoting Mcl-1 expression and eIF4E activity, and given the oncogenic role of these factors, we underscore the therapeutic potential of Notch inhibition in CLL.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Falco et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: